merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>Significant safety risks, including swelling and bleeding in the brain</answer>
<question_number>2</question_number>
<answer>It might discourage patients from participating in trials for treatments that could be better</answer>
<question_number>3</question_number>
<answer>No correlation between the removal of amyloid plaques and the clinical response in individual subjects</answer>
<question_number>4</question_number>
<answer>It may raise concerns about Kisunla's safety</answer>
<question_number>5</question_number>
<answer>Patients can stop Kisunla after their plaques are cleared, potentially reducing overall cost</answer>
<question_number>6</question_number>
<answer>It might discourage participation in other clinical trials</answer>
<question_number>7</question_number>
<answer>Patients can stop dosing after the target amyloid is cleared</answer>
<question_number>8</question_number>
<answer>Amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>Participants with intermediate tau levels declined more slowly than those with high levels</answer>